Bladder Cancer

Song Jiang, MD, PhD, discusses the balance between efficacy and safety data when considering the role for BCG/ICI combinations in BCG-naive NMIBC.

Neoadjuvant sacituzumab govitecan plus pembrolizumab yielded a clinical complete response rate of 39%, supporting the potential for bladder preservation.

In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.

The FDA granted priority review to EV plus pembrolizumab as a perioperative regimen for cisplatin-eligible MIBC based on KEYNOTE-B15 data showing a 47% reduction in EFS events, a 35% reduction in the risk of death, and a pCR rate of 55.8% vs 32.5% with standard chemotherapy.

"Parastomal hernia repair can be performed either open or robotically, according to the surgeon’s preference. The 2 mainstays of repair are the keyhole and intraperitoneal Sugarbaker repairs," Wyre writes.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Dr Alfonso Gómez de Liaño Lista for a timely discussion on a practice-changing development in muscle-invasive bladder cancer: the phase 3 KEYNOTE-B15 trial.

Adding pembrolizumab to trimodality therapy demonstrated encouraging activity in patients with muscle-invasive bladder cancer.

Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.

The findings highlight the potential of field-effect-informed liquid biopsy methods to guide adjuvant treatment decisions in NMIBC.

David Morris, MD, FACS, highlights key strategies for counseling patients receiving the gemcitabine intravesical system as well as considerations for maintaining patients on therapy long enough to achieve meaningful clinical benefit.

Jonathan F. Anker, MD, PhD, discusses findings from the phase 2 HCRN GU 20-444 trial, evaluating a response-adapted, bladder-sparing approach using pembrolizumab monotherapy in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin chemotherapy.

ImmunityBio has submitted a formal response to the FDA and initiated corrective actions.

Alexandra Drakaki, MD, discusses guidance from a modified Delphi panel on managing peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma receiving enfortumab vedotin.

David Morris, MD, FACS, discusses expert panel recommendations on intravesical drug-releasing systems in bladder cancer, highlighting early drug release dynamics, tolerability, and optimizing patient comfort.

The code, J9183, may be used by physicians and treatment centers for billing and reimbursement beginning April 1, 2026.

Christopher M. Pieczonka, MD, discusses practical strategies to optimize tolerability and minimize early discontinuation with indwelling intravesical drug-releasing systems for bladder cancer.

Despite promising candidates across tumor, immune, and systemic marker categories, no biomarker yet reliably predicts BCG response or identifies which NMIBC patients would benefit from adding checkpoint inhibitor therapy—a gap that limits informed shared decision-making and broader adoption of IO-BCG combinations despite positive trial data.

Meri-Margaret Deoudes discusses findings from the Bladder Cancer Advocacy Network’s "New Faces of Bladder Cancer" survey.

The company remains on track to submit a supplemental Biologics License Application in the fourth quarter of 2026.

The 5-factor model aims to refine treatment decision-making by stratifying patients into 3 clinically actionable subgroups.

The label update permits thawing of nadofaragene in a 25 °C water bath over approximately 25 minutes.

Bogdana Schmidt, MD, MPH, identified several subgroups most likely to harbor occult systemic disease and therefore potentially benefit from adding immunotherapy to BCG:

Matthew D. Galsky, MD, discusses the mechanism of action for FX-909, a first-in-class agent targeting PPARγ in advanced urothelial carcinoma.

The NCCN now assigns a Category 2A recommendation for nadofaragene in patients with high-risk BCG-unresponsive NMIBC with papillary tumors without CIS.

Christopher M. Pieczonka, MD, discusses the design and interim findings from the phase 2 QUILT 2.005 trial.